Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519043 | 0.81 | IP6K1 (0.43) | HRH3 | |
| SCHEMBL22138868 | 0.75 | HRH3 (0.71) | HRH3GPR119FPR2PROKR1EPHX2 | |
| SCHEMBL5024491 | 0.75 | HRH3 (0.71) | HRH3GPR119FPR2PROKR1EPHX2 | |
| SCHEMBL20076154 | 0.73 | HRH3 (0.54) | HRH3GPR119FPR2PROKR1TRPC6 | |
| SCHEMBL21130985 | 0.72 | HRH3 (0.67) | HRH3GPR119FPR2PROKR1EPHX2 | |
| SCHEMBL247758 | 0.72 | HRH3 (0.71) | HRH3GPR119FPR2PROKR1EPHX2 | |
| SCHEMBL2707675 | 0.71 | HRH3 (0.61) | HRH3GPR119FPR2PROKR1EPHX2 | |
| SCHEMBL7061476 | 0.71 | HRH3 (0.71) | HRH3GPR119FPR2PROKR1EPHX2 | |
| SCHEMBL506979 | 0.71 | HRH3 (0.71) | HRH3GPR119FPR2PROKR1EPHX2 | |
| SCHEMBL4237757 | 0.71 | HRH3 (0.53) | HRH3GPR119FPR2PROKR1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697307-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1697307-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-12 | — | — | EP | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| EP-1697307-A1 | OPIOID RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061442-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010558-A1 | Opioid receptor antagonists | OPRM1, OPRK1, OPRL1 | HRH3 669/4885GPR119 17/4885FPR2 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.